Literature DB >> 15939744

Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes.

Andrea Merlo1, Claudya Tenca, Franco Fais, Lorenzo Battini, Ermanno Ciccone, Carlo E Grossi, Daniele Saverino.   

Abstract

Class switching consists in the substitution of the heavy-chain constant region of immunoglobulin M (IgM) with that of IgG, IgA, or IgE. This enables antibodies to acquire new effector functions that are crucial to combat invading pathogens. Class switching usually requires engagement of CD40 on B cells by CD40 ligand (CD40L) on antigen-activated CD4(+) T cells and the production of cytokines. The process must be regulated tightly because abnormal IgG and IgA production favors the onset of autoimmunity, whereas increased switching to IgE leads to atopy. These inflammatory disorders can be triggered or exacerbated by costimulatory signals. Although thoroughly investigated on T cells, the roles of the inhibitory receptors CD85j, LAIR-1, and CD152 on B-cell functions have not been fully elucidated. In this study we show that cross-linking of the B-cell inhibitory receptors by specific monoclonal antibodies inhibits IgG and IgE production, reduces the percentage of IgG- and IgE-expressing B cells, and down-regulates interleukin 8 (IL-8), IL-10, and tumor necrosis factor alpha production. These effects were demonstrated using different B-cell stimulatory pathways (recall antigens, CD40L-transfected cells plus IL-4, and lipopolysaccharide plus IL-4). It thus appears that CD85j, LAIR-1, and CD152 play a central role for the control of IL-4-driven isotype switching.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939744      PMCID: PMC1151979          DOI: 10.1128/CDLI.12.6.705-712.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  34 in total

1.  Activation of lymphocytes by BAT and anti CTLA-4: comparison of binding to T and B cells.

Authors:  A Raiter; A Novogrodsky; B Hardy
Journal:  Immunol Lett       Date:  1999-08-03       Impact factor: 3.685

2.  Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activation.

Authors:  B A Binstadt; K M Brumbaugh; C J Dick; A M Scharenberg; B L Williams; M Colonna; L L Lanier; J P Kinet; R T Abraham; P J Leibson
Journal:  Immunity       Date:  1996-12       Impact factor: 31.745

3.  A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules.

Authors:  D Cosman; N Fanger; L Borges; M Kubin; W Chin; L Peterson; M L Hsu
Journal:  Immunity       Date:  1997-08       Impact factor: 31.745

4.  Detection of intracellular cytokines by flow cytometry.

Authors:  T Jung; U Schauer; C Heusser; C Neumann; C Rieger
Journal:  J Immunol Methods       Date:  1993-02-26       Impact factor: 2.303

5.  Activated T cells can induce high levels of CTLA-4 expression on B cells.

Authors:  H M Kuiper; M Brouwer; P S Linsley; R A van Lier
Journal:  J Immunol       Date:  1995-08-15       Impact factor: 5.422

6.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

Authors:  F Rousset; E Garcia; T Defrance; C Péronne; N Vezzio; D H Hsu; R Kastelein; K W Moore; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

7.  Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells.

Authors:  J Péguet-Navarro; C Moulon; C Caux; C Dalbiez-Gauthier; J Banchereau; D Schmitt
Journal:  Eur J Immunol       Date:  1994-04       Impact factor: 5.532

8.  Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells.

Authors:  C Caux; C Massacrier; B Vanbervliet; C Barthelemy; Y J Liu; J Banchereau
Journal:  Int Immunol       Date:  1994-08       Impact factor: 4.823

9.  Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells.

Authors:  N F Go; B E Castle; R Barrett; R Kastelein; W Dang; T R Mosmann; K W Moore; M Howard
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

10.  Human B cell precursors proliferate and express CD23 after CD40 ligation.

Authors:  S Saeland; V Duvert; I Moreau; J Banchereau
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more
  31 in total

Review 1.  Mechanisms of checkpoint inhibition-induced adverse events.

Authors:  P Urwyler; I Earnshaw; M Bermudez; E Perucha; W Wu; S Ryan; L Mcdonald; S N Karagiannis; L S Taams; N Powell; A Cope; S Papa
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

2.  Differential gene expression levels might explain association of LAIR2 polymorphisms with pemphigus.

Authors:  Carolina Maciel Camargo; Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-12-31       Impact factor: 4.132

3.  Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages.

Authors:  David L Lamar; Cornelia M Weyand; Jörg J Goronzy
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

4.  The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFNα production.

Authors:  Irene Bonaccorsi; Claudia Cantoni; Paolo Carrega; Daniela Oliveri; Gabrielle Lui; Romana Conte; Michele Navarra; Riccardo Cavaliere; Elisabetta Traggiai; Marco Gattorno; Alberto Martini; Maria Cristina Mingari; Alessandro Moretta; Guido Ferlazzo
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

5.  IL-7-induced phosphorylation of the adaptor Crk-like and other targets.

Authors:  Francesca B Aiello; Tad Guszczynski; Wenqing Li; Julie A Hixon; Qiong Jiang; Deborah L Hodge; Tania Massignan; Chiara Di Lisio; Anand Merchant; Antonio D Procopio; Valentina Bonetto; Scott K Durum
Journal:  Cell Signal       Date:  2018-03-24       Impact factor: 4.315

6.  Coordinated regulation of NK receptor expression in the maturing human immune system.

Authors:  Dara M Strauss-Albee; Amir Horowitz; Peter Parham; Catherine A Blish
Journal:  J Immunol       Date:  2014-10-06       Impact factor: 5.422

7.  Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction.

Authors:  M Ines Pascoal Ramos; Linjie Tian; Dallas Flies; Linde Meyaard; Emma J de Ruiter; Chang Song; Ana Paucarmayta; Akashdip Singh; Eline Elshof; Saskia V Vijver; Jahangheer Shaik; Jason Bosiacki; Zachary Cusumano; Christina Jensen; Nicholas Willumsen; Morten A Karsdal; Linda Liu; Sol Langermann; Stefan Willems
Journal:  Elife       Date:  2021-06-14       Impact factor: 8.140

8.  Modulation of the inhibitory receptor leukocyte Ig-like receptor 1 on human natural killer cells.

Authors:  Nicholas L Li; Chelsea L Davidson; Atul Humar; Deborah N Burshtyn
Journal:  Front Immunol       Date:  2011-09-20       Impact factor: 7.561

9.  Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.

Authors:  Vafa Shahabi; David Berman; Scott D Chasalow; Lisu Wang; Zenta Tsuchihashi; Beihong Hu; Lisa Panting; Maria Jure-Kunkel; Rui-Ru Ji
Journal:  J Transl Med       Date:  2013-03-22       Impact factor: 5.531

10.  Serum LAIR-2 is increased in autoimmune thyroid diseases.

Authors:  Rita Simone; Giampaola Pesce; Princey Antola; Domenico F Merlo; Marcello Bagnasco; Daniele Saverino
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.